Processa Pharmaceuticals (PCSA) has released an update.
Processa Pharmaceuticals, Inc. has successfully regained compliance with NASDAQ’s minimum closing bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This positive development comes as the company’s stock price has consistently met or exceeded the $1.00 threshold, closing the chapter on any previous concerns regarding their listing status.
For further insights into PCSA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
